BACOPA: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews

Overview

Bacopa (Bacopa monnieri) is a plant that has been used for centuries in traditional Ayurvedic medicine. It is sometimes called Brahmi.

Bacopa might increase certain brain chemicals that are involved in thinking, learning, and memory. It might also protect brain cells from chemicals involved in Alzheimer disease.

Bacopa is commonly used for Alzheimer disease, memory and thinking skills, anxiety, and attention deficit-hyperactivity disorder (ADHD), but there is no good scientific evidence to support any of these uses.

Do not confuse bacopa with gotu kola. Both plants are sometimes called Brahmi.

Uses & Effectiveness

We currently have no information for BACOPA overview.

Side Effects

When taken by mouth: Bacopa is possibly safe when used in doses up to 600 mg daily for up to 12 weeks. Common side effects include stomach cramps, nausea, and dry mouth.

Special Precautions and Warnings

When taken by mouth: Bacopa is possibly safe when used in doses up to 600 mg daily for up to 12 weeks. Common side effects include stomach cramps, nausea, and dry mouth.

Pregnancy and breast-feeding: There isn't enough reliable information to know if bacopa is safe to use when pregnant or breast-feeding. Stay on the safe side and avoid use.

Children: Bacopa is possibly safe when taken by mouth by children 6-14 years old for up to 6 months.

Slow heart rate (bradycardia): Bacopa might slow down the heart rate. This could be a problem in people who already have a slow heart rate or other heart disease. If you have a heart condition, check with your healthcare provider before using bacopa.

Gastrointestinal tract blockage: Bacopa might make GI tract blockage worse. If you have a GI tract blockage, check with your healthcare provider before using bacopa.

Ulcers: Bacopa might make stomach ulcers worse. If you have stomach ulcers, check with your healthcare provider before using bacopa.

Lung conditions: Bacopa might make asthma or chronic obstructive pulmonary disease (COPD) worse. If you have asthma or COPD, check with your healthcare provider before using bacopa.

Thyroid disorders: Bacopa might increase levels of thyroid hormone. Bacopa should be used cautiously or avoided if you have a thyroid condition or take thyroid hormone medications.

Urinary tract blockage: Bacopa might make blockage of the urinary tract worse. If you have a urinary tract blockage, check with your healthcare provider before using bacopa.

Interactions

Moderate Interaction

Be cautious with this combination

Drying medications (Anticholinergic drugs) interacts with BACOPA
Bacopa can increase a chemical in the body called acetylcholine. Acetylcholine plays a big part in many important body functions. Some medications, called anticholinergic drugs, block the effects of acetylcholine in the body. Taking bacopa might decrease the effects of anticholinergic drugs.
Various medications used for glaucoma, Alzheimer disease, and other conditions (Cholinergic drugs) interacts with BACOPA
Bacopa can increase a chemical in the body called acetylcholine. Some medications that are used for glaucoma, Alzheimer disease, and other conditions, also increase acetylcholine levels. Taking bacopa with these medications might increase the chance of side effects.
Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with BACOPA
Some medications are changed and broken down by the liver. Bacopa might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with BACOPA
Some medications are changed and broken down by the liver. Bacopa might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with BACOPA
Some medications are changed and broken down by the liver. Bacopa might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with BACOPA
Some medications are changed and broken down by the liver. Bacopa might change how quickly the liver breaks down these medications. This could change the effects and side effects of these medications.
Cevimeline (Evoxac) interacts with BACOPA
Bacopa might change how quickly the body breaks down cevimeline. This could change the effects and side effects of cevimeline.

Minor Interaction

Be watchful with this combination

Thyroid hormone interacts with BACOPA
The body naturally produces thyroid hormones. Bacopa might increase how much thyroid hormone is produced. Taking bacopa with thyroid hormone might cause too much thyroid hormone in the body, and increase its effects and side effects.

Dosing

Bacopa has most often been used by adults in doses of 300-600 mg by mouth daily for 12 weeks. Speak with a healthcare provider to find out what dose might be best for a specific condition.

View References

REFERENCES:

Paetz D, Kruskemper G Gillich KH. Psychological test performance in hospitalized climacteric patients during treatment of internal disorders, with special emphasis on the effects of estrogens and progesterone. . Zeitschrift für Gerontologie. 1975;8(5):358-364.

Palagiano, A., Bulletti, C., Pace, M. C., DE, Ziegler D., Cicinelli, E., and Izzo, A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann.N.Y.Acad.Sci. 2004;1034:200-210. View abstract.

Papiernik-Berkhauer E. Double blind study of an agent to prevent preterm delivery among women at increased risk [Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature]. Edition Schering Serie IV 1970;Vol. 3:65-8.

Pisanty, S., Rafaely, B., and Polishuk, W. The effect of steroid hormones on buccal mucosa of menopausal women. Oral Surg.Oral Med.Oral Pathol. 1975;40(3):346-353. View abstract.

Porcu E. Intramuscular versus vaginal progesterone in assisted reproduction [abstract]. Fertility and Sterility 2003;Vol. 80(issue suppl3:S131 (Abs # P-32).)

Prentice, A., Deary, A. J., and Bland, E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane.Database.Syst.Rev. 2000;(2):CD002122. View abstract.

Preston, J. T., Cameron, I. T., Adams, E. J., and Smith, S. K. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br.J.Obstet.Gynaecol. 1995;102(5):401-406. View abstract.

Propst, A. M., Hill, J. A., Ginsburg, E. S., Hurwitz, S., Politch, J., and Yanushpolsky, E. H. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil.Steril. 2001;76(6):1144-1149. View abstract.

Recker, R. R., Davies, K. M., Dowd, R. M., and Heaney, R. P. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial. Ann.Intern.Med. 6-1-1999;130(11):897-904. View abstract.

Redei, E. and Freeman, E. W. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995;20(3):259-267. View abstract.

Reijnders, F. J., Thomas, C. M., Doesburg, W. H., Rolland, R., and Eskes, T. K. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. Br.J.Obstet.Gynaecol. 1988;95(5):462-468. View abstract.

Rettenbacher, M. A., Mechtcheriakov, S., Bergant, A., Brugger, A., and Fleischhacker, W. W. Improvement of psychosis during treatment with estrogen and progesterone in a patient with hypoestrogenemia. J.Clin.Psychiatry 2004;65(2):275-277. View abstract.

Richter MA, Haltvick R Shapiro SS. Progesterone treatment of premenstrual syndrome. Current Therapeutic Research. 1984;36(5, Sect 2):840-850.

Rigaud, A. S., Andre, G., Vellas, B., Touchon, J., and Pere, J. J. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology 1-14-2003;60(1):148-149. View abstract.

Riis, B., Thomsen, K., and Christiansen, C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. N.Engl.J Med. 1-22-1987;316(4):173-177. View abstract.

Roglio, I., Giatti, S., Pesaresi, M., Bianchi, R., Cavaletti, G., Lauria, G., Garcia-Segura, L. M., and Melcangi, R. C. Neuroactive steroids and peripheral neuropathy. Brain Res.Rev. 2008;57(2):460-469. View abstract.

Rosenberg, S. M., Luciano, A. A., and Riddick, D. H. The luteal phase defect: the relative frequency of, and encouraging response to, treatment with vaginal progesterone. Fertil.Steril. 1980;34(1):17-20. View abstract.

Rouse, D. J., Caritis, S. N., Peaceman, A. M., Sciscione, A., Thom, E. A., Spong, C. Y., Varner, M., Malone, F., Iams, J. D., Mercer, B. M., Thorp, J., Sorokin, Y., Carpenter, M., Lo, J., Ramin, S., Harper, M., and Anderson, G. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N.Engl.J.Med. 8-2-2007;357(5):454-461. View abstract.

Ryan, N. and Rosner, A. Quality of life and costs associated with micronized progesterone and medroxyprogesterone acetate in hormone replacement therapy for nonhysterectomized, postmenopausal women. Clin.Ther. 2001;23(7):1099-1115. View abstract.

Saarikoski, S., Yliskoski, M., and Penttila, I. Sequential use of norethisterone and natural progesterone in pre-menopausal bleeding disorders. Maturitas 1990;12(2):89-97. View abstract.

Sampson, G. A. Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br.J.Psychiatry 1979;135:209-215. View abstract.

Sandyk, R. Estrogen's impact on cognitive functions in multiple sclerosis. Int.J.Neurosci. 1996;86(1-2):23-31. View abstract.

Saucedo LLE, Galache VP Hernandez AS Santos HR Arenas ML Patrizio P. Randomized trial of three different forms of progesterone supplementation in ART: preliminary results [abstract]. Fertility and Sterility 2000;74((Suppl 1):S150 (Abs # P-175).)

Saucedo-de la Llata E, Batiza V Arenas L Santos R Galache P Hernandez-Ayup S et al. Progesterone for luteal support: randomized, prospective trial comparing vaginal and i.m. administration [abstract]. Human Reproduction 2003;

Schaller, J. L., Briggs, B., and Briggs, M. Progesterone organogel for premenstrual dysphoric disorder. J.Am.Acad.Child Adolesc.Psychiatry 2000;39(5):546-547. View abstract.

Schussler, P., Kluge, M., Yassouridis, A., Dresler, M., Held, K., Zihl, J., and Steiger, A. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology 2008;33(8):1124-1131. View abstract.

SHEARMAN, R. P. and GARRETT, W. J. Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. Br.Med.J. 2-2-1963;1(5326):292-295. View abstract.

Shippen, E. R. and West, W. J., Jr. Successful treatment of severe endometriosis in two premenopausal women with an aromatase inhibitor. Fertil.Steril. 2004;81(5):1395-1398. View abstract.

Shu, J., Miao, P., and Wang, R. J. [Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody-positive early recurrent spontaneous abortion]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 2002;22(6):414-416. View abstract.

Soderpalm, A. H., Lindsey, S., Purdy, R. H., Hauger, R., and Wit, de H. Administration of progesterone produces mild sedative-like effects in men and women. Psychoneuroendocrinology 2004;29(3):339-354. View abstract.

Sofuoglu, M., Mitchell, E., and Kosten, T. R. Effects of progesterone treatment on cocaine responses in male and female cocaine users. Pharmacol.Biochem.Behav. 2004;78(4):699-705. View abstract.

Song, Y. L. and Zhu, L. P. [The fetus protection effects of Zhixue Baotai Decoction on women of early threatened abortion with dark area surrounding pregnancy sac]. Zhongguo Zhong.Xi.Yi.Jie.He.Za Zhi. 2007;27(11):1025-1028. View abstract.

Steffen, A. M., Thompson, L. W., Gallagher-Thompson, D., and Koin, D. Physical and psychosocial correlates of hormone replacement therapy with chronically stressed postmenopausal women. J.Aging Health 1999;11(1):3-26. View abstract.

Stein, D., Blumensohn, R., and Witztum, E. Perimenstrual psychosis among female adolescents: two case reports and an update of the literature. Int.J.Psychiatry Med. 2003;33(2):169-179. View abstract.

Strohl, K. P., Hensley, M. J., Saunders, N. A., Scharf, S. M., Brown, R., and Ingram, R. H., Jr. Progesterone administration and progressive sleep apneas. JAMA 3-27-1981;245(12):1230-1232. View abstract.

Sumita S, Sofat S Sr. Intramuscular versus intravaginal progesterone as luteal phase and early pregnancy support in patients undergoing IVF-ET [abstract]. Fertility and Sterility 2003;

SWYER, G. I. and DALEY, D. Progesterone implantation in habitual abortion. Br.Med.J. 5-16-1953;1(4819):1073-1077. View abstract.

Tognoni, G., Ferrario, L., Inzalaco, M., and Crosignani, P. G. Progestagens in threatened abortion. Lancet 12-6-1980;2(8206):1242-1243. View abstract.

Toh, Y. C., Jain, J., Rahnny, M. H., Bode, F. R., and Ross, D. Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 mL) contraceptive formulation in Asian women. Clin.Ther. 2004;26(11):1845-1854. View abstract.

Torode HW, Porter RN Vaughan JI Saunders DM. Luteal phase support after in vitro fertilisation: a trial and rationale for selective use. Clinical Reproduction and Fertility 1987;5:255-61.

Trotter, A., Maier, L., Grill, H. J., Kohn, T., Heckmann, M., and Pohlandt, F. Effects of postnatal estradiol and progesterone replacement in extremely preterm infants. J.Clin.Endocrinol.Metab 1999;84(12):4531-4535. View abstract.

Trotter, A., Maier, L., Grill, H. J., Wudy, S. A., and Pohlandt, F. 17Beta-estradiol and progesterone supplementation in extremely low-birth-weight infants. Pediatr.Res. 1999;45(4 Pt 1):489-493. View abstract.

Ugur M, Yenicesu O Ozcan S Keles G Gokmen O. A prospective randomized study comparing hCG, vaginalmicronized porgesterone and a combination regimen for luteal phase support in an in-vitro fertilization programme [abstract]. 2001;

Van der Meer YG, Benedek-Jaszmann LJ Van Loenen AC. Effect of high-dose progesterone on the pre-menstrual syndrome: A double-blind cross-over trial. . Journal of Psychosomatic Obstetrics & Gynecology 1983;2(4):220-222.

Van der Meer YG, Loendersloot EW Van Loenen AC. Effect of high-dose progesterone in post-partum depression. Journal of Psychosomatic Obstetrics & Gynecology.1 1984;3(1): 67-68.

Bhattacharya, S. K., Bhattacharya, A., Kumar, A., and Ghosal, S. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res 2000;14(3):174-179. View abstract.

Chaudhuri, P. K., Srivastava, R., Kumar, S., and Kumar, S. Phytotoxic and antimicrobial constituents of Bacopa monnieri and Holmskioldia sanguinea. Phytother.Res. 2004;18(2):114-117. View abstract.

Dar, A. and Channa, S. Calcium antagonistic activity of Bacopa monniera on vascular and intestinal smooth muscles of rabbit and guinea-pig. J Ethnopharmacol. 1999;66(2):167-174. View abstract.

Garai, S., Mahato, S. B., Ohtani, K., and Yamasaki, K. Bacopasaponin D--a pseudojujubogenin glycoside from Bacopa monniera. Phytochemistry 1996;43(2):447-449. View abstract.

Garai, S., Mahato, S. B., Ohtani, K., and Yamasaki, K. Dammarane-type triterpenoid saponins from Bacopa monniera. Phytochemistry 1996;42(3):815-820. View abstract.

Goel, R. K., Sairam, K., Babu, M. D., Tavares, I. A., and Raman, A. In vitro evaluation of Bacopa monniera on anti-Helicobacter pylori activity and accumulation of prostaglandins. Phytomedicine. 2003;10(6-7):523-527. View abstract.

Kar, A., Panda, S., and Bharti, S. Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice. J Ethnopharmacol. 2002;81(2):281-285. View abstract.

Kishore, K. and Singh, M. Effect of bacosides, alcoholic extract of Bacopa monniera Linn. (brahmi), on experimental amnesia in mice. Indian J Exp.Biol 2005;43(7):640-645. View abstract.

Mukherjee, G. D. and Dey, C. D. Clinical trial on Brahmi. I. J.Exp.Med.Sci. 1966;10(1):5-11. View abstract.

Pawar, R., Gopalakrishnan, C., and Bhutani, K. K. Dammarane triterpene saponin from Bacopa monniera as the superoxide inhibitor in polymorphonuclear cells. Planta Med. 2001;67(8):752-754. View abstract.

Rao, C. V., Sairam, K., and Goel, R. K. Experimental evaluation of Bocopa monniera on rat gastric ulceration and secretion. Indian J Physiol Pharmacol. 2000;44(4):435-441. View abstract.

Rastogi, S., Pal, R., and KulshreshthaDK. Bacoside A3--a triterpenoid saponin from Bacopa monniera. Phytochemistry 1994;36(1):133-137. View abstract.

Roodenrys, S., Booth, D., Bulzomi, S., Phipps, A., Micallef, C., and Smoker, J. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology 2002;27(2):279-281. View abstract.

Russo, A., Izzo, A. A., Borrelli, F., Renis, M., and Vanella, A. Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage. Phytother.Res. 2003;17(8):870-875. View abstract.

Sharma, R, Chaturvedi, C, and Tewari, PV. Efficacy of Bacopa monniera in revitalizing intellectual functions in children. J Res Edu Ind Med 1987;1-12.

Singh, H. K. and Dhawan, B. N. Effect of Bacopa monniera Linn. (brahmi) extract on avoidance responses in rat. J Ethnopharmacol. 1982;5(2):205-214. View abstract.

Singh, R. H. and Singh, L. Studies on the Anti-Anxiety Effect of the Medhya Rasayana Drug, Brahmi (Bacopa monniera Wettst.) - Part I. Journal of Research in Ayurveda and Siddha 1980;1(1):133-148.

Sumathy, T., Subramanian, S., Govindasamy, S., Balakrishna, K., and Veluchamy, G. Protective role of Bacopa monniera on morphine induced hepatotoxicity in rats. Phytother Res 2001;15(7):643-645. View abstract.

Vohora, SB, Khanna, T, Athar, M, and Ahmad, B. Analgesic activity of bacosine, a new triterpene isolated from Bacopa monnieri. Fitoterapia 1997;68(4):361-365.

Acquarulo B, Tandon P, Macica CM. Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report. J Med Case Rep 2022;16(1):253. View abstract.

Best T, Clarke C, Nuzum N, Teo WP. Acute effects of combined Bacopa, American ginseng and whole coffee fruit on working memory and cerebral haemodynamic response of the prefrontal cortex: a double-blind, placebo-controlled study. Nutr Neurosci. 2019:1-12. View abstract.

Dave UP, Dingankar SR, Saxena VS, et al. An open-label study to elucidate the effects of standardized Bacopa monnieri extract in the management of symptoms of attention-deficit hyperactivity disorder in children. Adv Mind Body Med 2014;28(2):10-5. View abstract.

Devi K, Bali A, Bhatia P, Singh N, Jaggi AS. Exploring the ameliorative potential of Bacopa monnieri in acetic acid induced ulcerative colitis in mice. Nat Prod Res 2023. View abstract.

Kar A, Pandit S, Mukherjee K, Bahadur S, Mukherjee PK. Safety assessment of selected medicinal food plants used in Ayurveda through CYP450 enzyme inhibition study. J Sci Food Agric 2017;97(1):333-40. doi: 10.1002/jsfa.7739. View abstract.

Kean JD, Downey LA, Sarris J, Kaufman J, Zangara A, Stough C. Effects of Bacopa monnieri (CDRI 08®) in a population of males exhibiting inattention and hyperactivity aged 6 to 14?years: a randomized, double-blind, placebo-controlled trial. Phytother Res 2022;36(2):996-1012. View abstract.

Keegan AP, Stough C, Paris D, et al. Bacopa monnieri supplementation has no effect on serum brain-derived neurotrophic factor levels but beneficially modulates nuclear factor kappa B and cyclic AMP response element-binding protein levels in healthy elderly subjects. J Clin Transl Res 2023;9(1):50-58. View abstract.

Kidd PM. A review of nutrients and botanicals in the integrative management of cognitive dysfunction. Altern Med Rev 1999;4:144-61.. View abstract.

Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, et al. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol 2014;151(1):528-35. View abstract.

Limpeanchob N, Jaipan S, Rattanakaruna S, et al. Neuroprotective effect of Bacopa monnieri on beta-amyloid-induced cell death in primary cortical culture. J Ethnopharmacol 2008;120:112-7. View abstract.

McPhee GM, Downey LA, Wesnes KA, Stough C. The neurocognitive effects of Bacopa monnieri and cognitive training on markers of brain microstructure in healthy older adults. Front Aging Neurosci 2021;13:638109. View abstract.

Micheli L, Spitoni S, Di Cesare Mannelli L, Bilia AR, Ghelardini C, Pallanti S. Bacopa monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation. Phytother Res. 2020. View abstract.

Minale G, Saesong T, Temkitthawon P, et al. Characterization of metabolites in plasma, urine and feces of healthy participants after taking brahmi essence for twelve weeks using LC-ESI-QTOF-MS metabolomic approach. Molecules 2021;26(10):2944. View abstract.

Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med 2010;16:753-9. View abstract.

Prabhakar S, Vishnu VY, Modi M, et al. Efficacy of Bacopa monnieri (Brahmi) and donepezil in Alzheimer's disease and mild cognitive impairment: a randomized double-blind parallel phase 2b study. Ann Indian Acad Neurol 2020;23(6):767-73. View abstract.

Ramasamy S, Kiew LV, Chung LY. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules 2014;19(2):2588-601. View abstract .

Samiulla DS, Prashanth D, Amit A. Mast cell stabilising activity of Bacopa monnieri. Fitoterapia 2001;72:284-5.. View abstract.

Santos AFD, Souza MMQ, Amaral EC, et al. Bacopa monnieri in Patients with Parkinson's Disease: A Pilot Study. J Med Food 2023;26(2):114-119. View abstract.

Shoukat S, Zia MA, Uzair M, et al. Synergistic neuroprotection by phytocompounds of Bacopa monnieri in scopolamine-induced Alzheimer's disease mice model. Mol Biol Rep 2023;50(10):7967-7979. View abstract.

Singh M, Murthy V, Ramassamy C. Modulation of hydrogen peroxide and acrolein-induced oxidative stress, mitochondrial dysfunctions and redox regulated pathways by the Bacopa monniera extract: potential implication in Alzheimer's disease. J Alzheimers Dis 2010;21:229-47. View abstract.

Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology 2001;156:481-4.. View abstract.

Stough C, Singh H, Zangara A. Mechanisms, efficacy, and safety of Bacopa monnieri (bacopa) for cognitive and brain enhancement. Evid Based Complement Alternat Med 2015;2015:717605. View abstract.

Tamoli SM, Harit MK, Mundhe N, Pande SP, Damle N, Chavan S, Kamde R, Pawar VA, Mahadik S. Nicotine Free Herbal Composition for Smoking De-Addiction - A Placebo Controlled, Double Blind, Randomized, Multicentric Clinical Study. J Pharm Bioallied Sci. 2023;15(2):88-94. View abstract.

Uabundit N, Wattanathorn J, Mucimapura S, Ingkaninan K. Cognitive enhancement and neuroprotective effects of Bacopa monnieri in Alzheimer's disease model. J Ethnopharmacol 2010;127:26-31. View abstract.

Yadav SK, Jain AK, Tripathi SN, Gupta JP. Irritable bowel syndrome: therapeutic evaluation of indigenous drugs. Indian J Med Res 1989;90:496-503.. View abstract.

Yaworski AM, Blyumin M, Chang T, Mammen AL, Greene M. Necrotizing myopathy with elevated anti-HMGCR antibodies following exposure to the supplement Bacopa. Muscle Nerve 2023;67(2):E1-E3. View abstract.

Young LM, Gauci S, Arnoldy L, et al. Investigating the Effects of a Multinutrient Supplement on Cognition, Mood and Biochemical Markers in Middle-Aged Adults with 'Optimal' and 'Sub-Optimal' Diets: A Randomized Double Blind Placebo Controlled Trial. Nutrients. 2022;14(23):5079. View abstract.

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2024 by Therapeutic Research Center, LLC. All Rights Reserved.

BACOPA - Uses, Side Effects, and More

Overview

Uses & Effectiveness

Side Effects

Special Precautions and Warnings

Interactions

Moderate Interaction

Drying medications (Anticholinergic drugs) interacts with BACOPA

Various medications used for glaucoma, Alzheimer disease, and other conditions (Cholinergic drugs) interacts with BACOPA

Medications changed by the liver (Cytochrome P450 1A2 (CYP1A2) substrates) interacts with BACOPA

Medications changed by the liver (Cytochrome P450 2C19 (CYP2C19) substrates) interacts with BACOPA

Medications changed by the liver (Cytochrome P450 2C9 (CYP2C9) substrates) interacts with BACOPA

Medications changed by the liver (Cytochrome P450 3A4 (CYP3A4) substrates) interacts with BACOPA

Cevimeline (Evoxac) interacts with BACOPA

Minor Interaction

Thyroid hormone interacts with BACOPA

Dosing